# A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

> **NCT06809569** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Allyl Isothiocyanate (AITC)
- **DRUG:** Capsaicin
- **OTHER:** Vehicle for AITC
- **OTHER:** Vehicle for Capsaicin

## Key facts

- **NCT ID:** NCT06809569
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-25
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809569, "A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06809569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*